OKYO Pharma Ltd (OKYO) CSO buys 3,363 shares at $1.49
Rhea-AI Filing Summary
OKYO Pharma Ltd reported that Chief Scientific Officer Rajkumar V. Patil made an open market purchase of 3,363 shares of common stock on July 27, 2026 at $1.49 per share. Following this transaction, he directly owns 20,030 shares. This Form 4/A corrects only the transaction code, and the transaction was not reported under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,363 shares
Net Buy
1 txn
Insider
Patil Rajkumar V.
Role
Chief Scientific Officer
Bought
3,363 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 3,363 | $1.49 | $5K |
Holdings After Transaction:
COMMON STOCK — 20,030 shares (Direct)
Key Figures
Shares purchased: 3,363 shares
Purchase price per share: $1.49
Shares owned after transaction: 20,030 shares
+2 more
5 metrics
Shares purchased
3,363 shares
Open market purchase on July 27, 2026
Purchase price per share
$1.49
Price paid for each share in the July 27, 2026 trade
Shares owned after transaction
20,030 shares
Direct holdings of Rajkumar V. Patil following the purchase
Net shares bought
3,363 shares
Net buy volume reported in this Form 4/A
Buy transactions reported
1
Single non-derivative open market purchase in this amendment
Key Terms
Form 4/A, open market purchase, direct ownership, Chief Scientific Officer
4 terms
Form 4/A regulatory
"This Form 4/A amends the Form 4 filed on July 29, 2026"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
open market purchase financial
"correct the transaction code associated with this open market purchase"
An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.
direct ownership financial
"The reporting person has direct ownership of the shares"
Chief Scientific Officer medical
"Patil Rajkumar V. serves as Chief Scientific Officer"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did OKYO (OKYO) disclose in this Form 4/A?
OKYO Pharma disclosed that Chief Scientific Officer Rajkumar V. Patil bought 3,363 shares of common stock in an open market purchase on July 27, 2026 at $1.49 per share, increasing his directly held stake.
Why did OKYO (OKYO) file an amended Form 4/A for this insider trade?
The amended Form 4/A was filed solely to correct the transaction code for this open market purchase. OKYO Pharma stated that no other reported transactions were affected, so only the coding of this purchase was revised.
Was the OKYO (OKYO) insider purchase made under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox was not marked as affirmative, indicating the 3,363-share open market purchase by Rajkumar V. Patil was not reported as being executed under a Rule 10b5-1 trading plan.